The Aurora Funds

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Digitalsmiths is a technology company based in Durham, North Carolina, specializing in video indexing and digital content publishing. Founded in 2006, it provides video providers with the tools to access video archives and deliver personalized viewing experiences through precise and actionable video metadata. Its solutions are versatile, supporting various content formats and devices, which enhances user engagement and monetization opportunities across mobile, broadband, tablet, and television platforms. Digitalsmiths serves prominent clients in the entertainment industry, including major Hollywood studios, broadcasters, and publishers. The company's innovative algorithms facilitate effective video search and interpretation, allowing content owners and advertisers to maximize the value of their digital video assets.

Centice Corporation specializes in developing devices for drug detection and identification. The company offers solutions for identifying prescription drugs, illicit substances, and mixtures, as well as addressing issues related to narcotics enforcement and counterfeiting. Its notable product, the PASS Rx system, enhances the verification process for dispensed medications by capturing the spectral signature of drugs and comparing it to a known database. Founded in 2003 and headquartered in Morrisville, North Carolina, Centice operates through a network of distributors both domestically and internationally, providing vital tools for drug verification and safety. The company was formerly known as Optopo, Inc. and rebranded to Centice Corporation in February 2008.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.

Digitalsmiths is a technology company based in Durham, North Carolina, specializing in video indexing and digital content publishing. Founded in 2006, it provides video providers with the tools to access video archives and deliver personalized viewing experiences through precise and actionable video metadata. Its solutions are versatile, supporting various content formats and devices, which enhances user engagement and monetization opportunities across mobile, broadband, tablet, and television platforms. Digitalsmiths serves prominent clients in the entertainment industry, including major Hollywood studios, broadcasters, and publishers. The company's innovative algorithms facilitate effective video search and interpretation, allowing content owners and advertisers to maximize the value of their digital video assets.

Centice Corporation specializes in developing devices for drug detection and identification. The company offers solutions for identifying prescription drugs, illicit substances, and mixtures, as well as addressing issues related to narcotics enforcement and counterfeiting. Its notable product, the PASS Rx system, enhances the verification process for dispensed medications by capturing the spectral signature of drugs and comparing it to a known database. Founded in 2003 and headquartered in Morrisville, North Carolina, Centice operates through a network of distributors both domestically and internationally, providing vital tools for drug verification and safety. The company was formerly known as Optopo, Inc. and rebranded to Centice Corporation in February 2008.

Digitalsmiths is a technology company based in Durham, North Carolina, specializing in video indexing and digital content publishing. Founded in 2006, it provides video providers with the tools to access video archives and deliver personalized viewing experiences through precise and actionable video metadata. Its solutions are versatile, supporting various content formats and devices, which enhances user engagement and monetization opportunities across mobile, broadband, tablet, and television platforms. Digitalsmiths serves prominent clients in the entertainment industry, including major Hollywood studios, broadcasters, and publishers. The company's innovative algorithms facilitate effective video search and interpretation, allowing content owners and advertisers to maximize the value of their digital video assets.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.

StemCo Biomedical, Inc. was founded in 1999 and is located in the Research Triangle Park area of NC. The Company is engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoetic stem and progenitor cells derived from bone marrow, peripheral blood or umbilical cord blood. Addressing a market of more than $1 billion annually, the Company will have a series of products on the market starting in 2002 that identify, sort and custom-engineer stem cell grafts based upon cellular expression of ALDH resulting in what may be better, more effective stem cell transplants in the future.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.

Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, particularly those that offer antidote-controlled solutions for managing anticoagulation. Founded in 2001 and headquartered in Durham, North Carolina, the company has developed REG1, a treatment for patients with acute coronary syndrome undergoing procedures such as coronary artery bypass grafting and percutaneous coronary intervention. Regado's innovative approach involves the use of antithrombotic aptamers combined with controlling agents, which target both arterial and venous thrombosis, aiming to enhance patient safety and treatment efficacy.

StemCo Biomedical, Inc. was founded in 1999 and is located in the Research Triangle Park area of NC. The Company is engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoetic stem and progenitor cells derived from bone marrow, peripheral blood or umbilical cord blood. Addressing a market of more than $1 billion annually, the Company will have a series of products on the market starting in 2002 that identify, sort and custom-engineer stem cell grafts based upon cellular expression of ALDH resulting in what may be better, more effective stem cell transplants in the future.

Opsware, Inc. is a software company located in Sunnyvale, California, specializing in data center automation products aimed at enterprise customers, government agencies, and service providers across various industries. Originally founded as Loudcloud in 1999, the company transitioned to Opsware after divesting its managed services division in 2002. Opsware's offerings focus on server and network device provisioning, configuration, and management, leveraging automated server life-cycle management technology developed in-house. The company expanded its capabilities through strategic acquisitions, including Tangram Enterprise Solutions in 2003 for asset management, Rendition Networks in 2004 for network device configuration, CreekPath in 2006 for storage provisioning, and iConclude in 2007 for run-book automation. In July 2007, HP announced its intention to acquire Opsware for $1.6 billion, marking one of its largest acquisitions.

Accipiter offers online advertising solutions and services worldwide. It offers AdManager, an ad management solution that allows to increase targeting capabilities to speed ad delivery and to monitor and control inventory projections in real-time; Ad Trafficking, which provides AdManager hosted clients with outsourced and customized solution to administer the campaign management process; AdMarket, a real-time bid-for-placement technology enabling publishers to operate branded online advertising marketplaces and transact with advertisers who are requesting a pay-per-click pricing model; and Visitor Interest Behavioral Engine, a behavioral targeting solution that delivers promotions and content to interested prospects. Accipiter is based in Raleigh, North Carolina with an additional office in London, United Kingdom.

Accipiter offers online advertising solutions and services worldwide. It offers AdManager, an ad management solution that allows to increase targeting capabilities to speed ad delivery and to monitor and control inventory projections in real-time; Ad Trafficking, which provides AdManager hosted clients with outsourced and customized solution to administer the campaign management process; AdMarket, a real-time bid-for-placement technology enabling publishers to operate branded online advertising marketplaces and transact with advertisers who are requesting a pay-per-click pricing model; and Visitor Interest Behavioral Engine, a behavioral targeting solution that delivers promotions and content to interested prospects. Accipiter is based in Raleigh, North Carolina with an additional office in London, United Kingdom.